Transplant News and Research

RSS

Taligen Therapeutics to highlight three pipeline candidates at XXIII ICW

Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced that preclinical data on three of its pipeline candidates will be highlighted at the XXIII International Complement Workshop taking place August 1-5, 2010, in New York City.

2 Aug 2010

Cardioxyl Pharmaceuticals achieves positive results in first clinical study of CXL-1020 for ADHF

Cardioxyl Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel therapeutic agents for the treatment of cardiovascular disease, today announced that it has achieved positive safety and tolerability results in the first clinical study of its lead drug candidate, CXL-1020, for the treatment of patients with acute decompensated heart failure. Each year in the United States, more than one million patients are hospitalized with acute heart failure.

2 Aug 2010

VBDS secondary to nevirapine use in HIV-positive, pregnant female: Report

Vanishing bile duct syndrome refers to a group of disorders characterized by destruction and disappearance of intrahepatic (inside the liver) bile ducts. Multiple causes have been identified including infections, malignancies, autoimmune conditions and adverse effects of medications. The usual course of this condition is variable and many patients with VBDS respond to treatment of the underlying condition and/ or removal of the offending agent. However, others progress to cirrhosis and end stage liver disease requiring liver transplantation.

31 Jul 2010

Gen-Probe second-quarter 2010 product sales up 14%

Gen-Probe Incorporated today reported financial results for the second quarter of 2010, highlighted by 14% growth in product sales, 15% growth in total revenues, and 16% growth in non-GAAP earnings per share.

30 Jul 2010

BioScrip second-quarter 2010 revenue increases 25% to $412.0 million

BioScrip, Inc. announced 2010 second quarter revenue of $412.0 million, operating income of $13.5 million and net income of $3.1 million, or $0.06 per diluted share. Second quarter adjusted earnings per share (detailed in schedule 5) was $0.07 per diluted share. Adjusted EBITDA for the quarter was $18.4 million. All 2010 per share amounts have been adjusted to reflect the Company's issuance of 13.1 million shares in conjunction with the acquisition of CHS.

30 Jul 2010

CPF announces nationwide advertising campaign to increase awareness about PF

The Coalition for Pulmonary Fibrosis announced today a nationwide advertising campaign to spread the word about Pulmonary Fibrosis is underway in an untraditional setting – on the nation's interstates. Together, a billboard ad and truck ads are part of a nationwide campaign to raise eyebrows and awareness of the deadly lung disease.

30 Jul 2010

Life Technologies second-quarter Non-GAAP revenue increases 8% to $906 million

Life Technologies Corporation today announced results for its second quarter ending June 30, 2010. Non-GAAP revenue for the second quarter was $906 million, an increase of 8 percent over the $839 million reported for the second quarter of 2009. Excluding the impact of currency and prior acquisitions and divestitures, organic revenue for the quarter grew 6 percent over the same period in the previous year.

30 Jul 2010

Intensive chemotherapy may benefit elderly patients with acute myeloid leukemia

The prognosis for nearly three-quarters of elderly patients on intensive chemotherapy for acute myeloid leukemia (AML) is poor, with a median survival of less than six months, according to a study published online today in Blood, the journal of the American Society of Hematology. AML is the most common form of acute leukemia among adults and is a rapidly growing cancer of the bone marrow that requires immediate treatment. The average age at diagnosis is 67, and more than 12,000 people will be diagnosed with AML this year (according to the National Cancer Institute).

29 Jul 2010

CMX157 shows potential to suppress replication of HIV in Phase 1 clinical trial

Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of research results demonstrating the potential of CMX157 (hexadecyloxypropyl tenofovir) to effectively suppress replication of human immunodeficiency virus (HIV) that cannot be treated with currently available nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), including tenofovir disoproxil fumarate (Viread), due to the development of multi-drug resistance. Earlier this year, Chimerix initiated a dose-escalating Phase 1 clinical trial of CMX-157 to evaluate drug safety, tolerability and pharmacokinetics.

29 Jul 2010

Limerick to announce new results from LIM-0705 human trials at 23rd Transplantation Society congress

Limerick BioPharma, Inc., a developer of innovative therapies that help cells pump out unwanted or toxic substances, will announce new results from human trials of its lead compound, LIM-0705, at the 23rd International Congress of the Transplantation Society in Vancouver, Canada, in an oral presentation on August 19, 2010.

29 Jul 2010

Clinical Pharmacokinetics Research Laboratory deploys AB SCIEX mass spectrometry technology

AB SCIEX, a global leader in life science analytical technologies, today announced that the Clinical Pharmacokinetics Research Laboratory at the University of Rhode Island's College of Pharmacy is using AB SCIEX mass spectrometry technology to develop a novel test that would enable clinical researchers to use saliva to monitor immunosuppressant drugs commonly administered to make organ transplants successful.

28 Jul 2010

Researchers establish new criteria for liver transplantation

Researchers at the University of California, San Francisco propose that treatments used on liver cancers beyond the established Milan criteria for liver transplantation may be appropriate for all patients with hepatocellular carcinoma who are listed for transplantation. Full details appear in the August issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

28 Jul 2010

Astellas extends non-exclusive license agreement with Regeneron for VelocImmune technology

Regeneron Pharmaceuticals, Inc. and Astellas Pharma Inc. announced that Astellas has extended through 2023 the non-exclusive license agreement that allows Astellas to utilize Regeneron's VelocImmune® technology in its internal research programs to discover fully human monoclonal antibody product candidates.

28 Jul 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

Genzyme accepts CMS decision for delaying Renvela administration to dialysis patients

Genzyme Corp.today said it welcomed the Centers for Medicare and Medicaid Services' decision not to include oral medications without IV equivalents in Medicare's End Stage Renal Disease patient benefit. According to the final rule, these medications, including Genzyme's Renvela (sevelamer carbonate), will not be included in the bundle until January 1, 2014.

28 Jul 2010

FDA approves addition of 10 sites to WorldHeart's Levacor VAD BTT clinical study

World Heart Corporation, a developer of mechanical circulatory systems, announced today that the United States Food and Drug Administration (FDA) has approved the addition of ten sites to the Levacor ventricular assist device (VAD) Bridge-to-Transplant (BTT) clinical study. WorldHeart's pivotal BTT study is now approved to enroll patients at 20 sites in the U.S.

28 Jul 2010

SBHCS deploys MedeAnalytics platform to automate patient access process of health system

MedeAnalytics, a leading provider of healthcare performance management solutions, today announced that the Saint Barnabas Health Care System has selected MedeAnalytics Patient Access Intelligence solution to automate the complete patient access process of the health system.

27 Jul 2010

New partnership brings latest stem cell discoveries from laboratory to patient

A major research company affiliated with the University of Colorado with expertise in managing clinical trials is partnering with the University of Colorado's Anschutz Medical Campus to more efficiently bring the latest stem cell discoveries from the laboratory to the patient.

27 Jul 2010

Waters to present MassTrak solutions at American Association of Clinical Chemistry annual meeting

Waters Corporation is showcasing its portfolio of MassTrak solutions at the American Association of Clinical Chemistry annual meeting and Clinical Lab Expo July 25 - 29, 2010 in Anaheim in exhibit booth #4447. Waters portfolio of MassTrak Solutions for the clinical laboratory combines the power of separations science, tandem mass spectrometry, specialized chemistries, software, and support services in ways designed to optimize laboratory processes.

27 Jul 2010

Abbot's innovative solutions to be highlighted at AACC

A first-of-its-kind test that detects HIV infection earlier than ever before in the United States; a molecular assay for identification of two common sexually transmitted diseases; and an enhanced integrated analyzer offering significant workflow improvements; are among the many new advances Abbott will highlight at this year's American Association for Clinical Chemistry Lab Expo which starts today in Anaheim.

27 Jul 2010

Transplant News and Research

Taligen Therapeutics to highlight three pipeline candidates at XXIII ICW

Cardioxyl Pharmaceuticals achieves positive results in first clinical study of CXL-1020 for ADHF

VBDS secondary to nevirapine use in HIV-positive, pregnant female: Report

Gen-Probe second-quarter 2010 product sales up 14%

BioScrip second-quarter 2010 revenue increases 25% to $412.0 million

CPF announces nationwide advertising campaign to increase awareness about PF

Life Technologies second-quarter Non-GAAP revenue increases 8% to $906 million

Intensive chemotherapy may benefit elderly patients with acute myeloid leukemia

CMX157 shows potential to suppress replication of HIV in Phase 1 clinical trial

Limerick to announce new results from LIM-0705 human trials at 23rd Transplantation Society congress

Clinical Pharmacokinetics Research Laboratory deploys AB SCIEX mass spectrometry technology

Researchers establish new criteria for liver transplantation

Astellas extends non-exclusive license agreement with Regeneron for VelocImmune technology

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Genzyme accepts CMS decision for delaying Renvela administration to dialysis patients

FDA approves addition of 10 sites to WorldHeart's Levacor VAD BTT clinical study

SBHCS deploys MedeAnalytics platform to automate patient access process of health system

New partnership brings latest stem cell discoveries from laboratory to patient

Waters to present MassTrak solutions at American Association of Clinical Chemistry annual meeting

Abbot's innovative solutions to be highlighted at AACC

Industry Focus eBook - Cell biology (5th edition) eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News